ERFSF - Eurofins Scientific Is A Growth Story That Has Reached Fair Valuation Again

2024-02-01 15:06:04 ET

Summary

• Eurofins Scientific is delivering a 10% growth without relying on exuberant COVID-related margins.
• The company boasts a robust business model, a significant market share, and a reliable and trustworthy management team.
• The stock has the potential to double by 2028 if the management projections are achieved.
• The current price is roughly 30% below my valuation.

Eurofins Scientific (ERFSF) is a growth story. The current stock price has experienced a 55% decline from its COVID peak; however, the company continues to exhibit a steady 10% annual growth rate, even without the exceptional COVID-related margins. I am positively inclined toward the business model, management approach, and growth potential. Consequently, I believe the company is reasonably valued, making it a good buying opportunity.

If you're considering buying the stock, I recommend doing so on Euronext Paris, where it is traded under the ticker ERF and has higher trading volume compared to the US....

For further details see: